MedTrace Logo

Unravelling Mechanisms of Fructose vs Glucose Consumption in the Pathogenesis and Progression of NAFLD

NCT02075164 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2020-09-07

No results posted yet for this study

Summary

Non-alcoholic fatty liver disease (NAFLD) comprises a spectrum ranging from simple fatty liver over steatohepatitis (NASH) to liver cirrhosis and cancer (HCC) and is a major and increasing health problem affecting nearly 40% of the general population. Moreover, NAFLD is an important risk factor for progression of diabetes and atherosclerosis. However, the pathomechanisms determining disease progression are poorly understood. The overall aim of this project is to test the central hypothesis that excessive fructose consumption provides a multiple metabolic hit in the pathogenesis and progression of NAFLD/NASH by impairment of hepatic lipid homeostasis and mitochondrial function resulting in hepatic lipotoxicity with inflammasome activation and disturbed interorgan cross-talk among insulin sensitive tissues.

Conditions

  • Non-alcoholic Fatty Liver Disease
  • Non-alcoholic Steatohepatitis

Interventions

DIETARY_SUPPLEMENT

Fructose

High oral Fructose challenge (150g per day for 56 days)

DIETARY_SUPPLEMENT

Glucose

Dietary Supplement: High oral Fructose challenge (167g per day for 56 days)

Sponsors & Collaborators

  • Wiener Wissenschafts-, Forschungs- und Technologiefonds

    collaborator UNKNOWN

  • Prof. Michael Trauner, MD

    lead OTHER

Principal Investigators

  • Michael Trauner, Prof. MD · Division of Gastroenterology and Hepatology Department of Internal Medicine III Medical University of Vienna

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2021-06-30
Completion
2021-12-31

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02075164 on ClinicalTrials.gov